Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with sensitive EGFR mutations.

Clinical lung cancer - 1 Mar 2026

Liu Zetao, Peng Zhiyu, Cao Jie, Huang Zhaokang, Liao Xizhou, Zong Xiaorong, Guo Chenglin, Mei Jiandong

Abstract excerpt

BACKGROUND: The prognosis of stage I non-small cell lung cancer (NSCLC) remains significant heterogeneity. It is not clear whether adjuvant epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy can reduce recurrence and improve survival in patients with stage I disease, especially stage IA. METHODS: This retrospective, single-center, observational, propensity score-matched study enrolled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 41274800
DOI: 10.1016/j.cllc.2025.09.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with sensitive EGFR mutations.PMID 41274800Read ↗

Risk Stratification and Adjuvant Chemotherapy Based on Clinical Risk Scores of Patients with Stage IB-IIA Non-Small Cell Lung CancerSemantic proximity Read ↗

Pooled Analysis of the Prognostic Significance of Epidermal Growth Factor Receptor (EGFR) Mutational Status in Combination with Other Driver Genomic Alterations in Stage I Resected Invasive Lung Adenocarcinoma for Recurrence-Free Survival: A Population-Based Study.Semantic proximity Read ↗

The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.Semantic proximity Read ↗

Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.Semantic proximity Read ↗

Risk Factors for Recurrence of Stage I Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis.Semantic proximity Read ↗

EGFR Mutation Impacts Recurrence in High-Risk Early-Stage Lung Adenocarcinoma in the IASLC Grading SystemSemantic proximity Read ↗

Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.Semantic proximity Read ↗

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.Semantic proximity Read ↗

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.Semantic proximity Read ↗

EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.